UK Markets closed


Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
35.350.00 (0.00%)
As of 3:03PM EDT. Market open.
People also watch
Full screen
Previous close35.35
Bid0.00 x
Ask0.00 x
Day's range0.00 - 0.00
52-week range
Avg. volume2,004
Market cap12.79B
PE ratio (TTM)22.41
EPS (TTM)1.58
Earnings dateN/A
Dividend & yield0.63 (1.80%)
Ex-dividend date2017-04-28
1y target estN/A
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US

    THOUSAND OAKS, Calif. and BRUSSELS, July 16, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologics License Application (BLA) for EVENITY™* (romosozumab) as a treatment for postmenopausal women with osteoporosis. The original submission included data from the pivotal Phase 3 placebo-controlled FRAME study of postmenopausal women with osteoporosis. The resubmission will also include the efficacy and safety data from the BRIDGE study, the Phase 3 trial evaluating EVENITY in men with osteoporosis, which has also been requested.

  • PR Newswirelast month

    Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy

    BRUSSELS, June 13, 2017 /PRNewswire/ -- UCB today presented results from CRIB, a pharmacokinetic study designed to assess if CIMZIA® (certolizumab pegol) is transferred across the placenta from pregnant women to their infants. The study used a sensitive immunoassay designed specifically to measure CIMZIA and found no measurable levels in 13 out of 14 infant blood samples at birth, and in all infant samples at weeks four and eight after birth.

  • TheStreet.com2 months ago

    UCB Stock Plunges After Trials Reveal Safety Risk in Amgen JV

    UCB stock plummeted Monday after clinical trials shone a light over a possible safety risk related to the Osteoporosis treatment that it has been developing alongside Amgen